Pharmaceutical Technology19h
MeiraGTx and Hologen launch AI-backed gene therapy venture
The venture aims to advance MeiraGTx’s Parkinson’s gene therapy through Phase III trials with up to $430m in funding from ...
Pharmabiz4d
Lundbeck’ amlenetug receives Japanese orphan drug designation for treatment of multiple system atrophy
Lundbeck’ amlenetug receives Japanese orphan drug designation for treatment of multiple system atrophy: Denmark Tuesday, March 11, 2025, 11:00 Hrs [IST] H. Lundbeck A/S (Lundbec ...
Alterity Therapeutics (ATHE): Among the Best Australian Stocks to Buy According to Billionaires
We recently published a list of 10 Best Australian Stocks to Buy According to Billionaires. In this article, we are going to ...
Theravance Biopharma: Clinical Progress Is Not Enough To Make It Attractive
Despite recent progress, significant risks remain, leading me to stay on the sidelines regarding investment in Theravance. Explore more details here.
H. Lundbeck A/S: Lundbeck's potential treatment for Multiple System Atrophy granted Orphan Drug Designation in Japan
The Ministry of Health, Labor, and Welfare (MHLW) in Japan has granted Orphan Drug Designation (ODD) to Lundbeck's investigational drug, amlenetug ...
10 Best Australian Stocks to Buy According to Billionaires
If you want to read more about the recent tariffs imposed by the US you can look at the 10 Most Undervalued High Quality ...